✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Clinical Reference

SELECT Trial Results

Released: Last reviewed:

SELECT (NEJM 2023, PMID 37952131): 20% MACE reduction in non-diabetic adults with overweight/obesity + established CVD. Led to Wegovy's 2024 FDA expansion for CV risk reduction.

Clinical referencePubMed-linked
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Overview

SELECT (NEJM 2023, PMID 37952131): 20% MACE reduction in non-diabetic adults with overweight/obesity + established CVD. Led to Wegovy's 2024 FDA expansion for CV risk reduction.

PubMed citations

Related clinical pages

Key facts, checked November 20, 2026

SELECT (NEJM 2023) enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. Over a mean follow-up of 39.8 months, a major cardiovascular event occurred in 6.5% of patients on semaglutide 2.4 mg and 8.0% on placebo (hazard ratio 0.80). Adverse events led 16.6% of patients on semaglutide to stop treatment, compared with 8.2% on placebo. On this evidence the Wegovy label includes cardiovascular risk reduction. SELECT tested Wegovy, not compounded semaglutide.